Search Results
Your search for ,waY matches 3838 pages
Showing 701 - 750Studies Show That Laws to Limit Opioid Prescribing Have Hampered Pain Control for Patients With Cancer
In 2015, an unprecedented phenomenon occurred in the United States: according to the World Bank Group, the nation’s average life expectancy fell from 78.8 years in 2014 to 78.7 years in 2015, then to 78.5 years in 2017. The last time our life expectancy registered a similar decline was in the years ...
Study Finds Patients With Lung Cancer Demonstrated Psychological Resilience in the Face of the COVID-19 Pandemic
Far from being hobbled by fears of COVID-19, patients with lung cancer actually showed less depression and anxiety during the pandemic than their healthy peers, according to results from a new study by Arrato et al published in JNCCN–Journal of the National Comprehensive Cancer Network. Researchers ...
RxPONDER Trial: Another Step in Defining Which Patients With Breast Cancer May Be Spared Adjuvant Cytotoxic Chemotherapy
As reported by Kalinsky et al and summarized in this issue of The ASCO Post, an interim analysis of the phase III RxPONDER trial showed that the addition of adjuvant chemotherapy to endocrine therapy improved invasive disease–free survival among premenopausal—but not postmenopausal—women with...
Jeffrey M. Farma, MD, FACS, Elected to Leadership Position in the Society of University Surgeons
Jeffrey M. Farma, MD, FACS, Chief of the Division of General Surgery and Co-Director of the Melanoma and Skin Cancer Program at Fox Chase Cancer Center, has been elected a member-at-large for the Society of University Surgeons. According to the society, the member-at-large position is an important...
Hematologist and Bone Marrow Transplant Pioneer, Tahir Shamsi, MBBS, MRCPath, FRCPath, Dies at 59
Although bone marrow transplantation is routinely employed in the United States and other wealthy nations, this costly life-saving procedure has struggled to gain a foothold in many low- to moderate-income countries, where resources are triaged to make the best use of precious health-care funding. ...
Datopotamab Deruxtecan Shows Activity in Advanced Triple-Negative Breast Cancer
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented...
AMA: CDC Quarantine and Isolation Guidance Is Confusing, Counterproductive
“Nearly 2 years into this pandemic, with Omicron cases surging across the country, the American people should be able to count on the Centers for Disease Control and Prevention (CDC) for timely, accurate, clear guidance to protect themselves, their loved ones, and their communities. Instead, the...
Adverse Event Rates After Two Doses of mRNA COVID-19 Vaccine in Patients With vs Without Cancer
New research published by Shulman et al in JNCCN—Journal of the National Comprehensive Cancer Network confirmed that mRNA vaccines for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from a single institution tracked short-term side effects from ...
Study Examines Role of Hyaluronic Acid in Pancreatic Cancer Growth
Hyaluronic acid is a known presence in pancreatic tumors, but a new study published by Kim et al in eLife has shown that hyaluronic acid can also act as a nutrient to fuel pancreatic cancer metabolism. These findings provide insight into how pancreatic cancer cells grow and indicate new...
Can Weight Loss in Adulthood Reduce the Risk of Developing Colorectal Adenomas?
Weight loss for adults, particularly those who are overweight or obese, may reduce their risk of developing a type of polyp that may lead to colorectal cancer, according to a new study published by He et al in JNCI Cancer Spectrum. Losing weight from early to late adulthood (up to the mid-70s)—at...
Kerryn Reding, PhD, MPH, RN, Daughter of Health-Care Workers, Chooses a Career in Breast Cancer Survivorship
Kerryn Reding, PhD, MPH, RN—whose research focuses on reducing cancer incidence and improving survival, with particular interests in lifestyle interventions and biomarkers of risk—was born in Australia, but her family moved to Iowa when she was a toddler. “Both of my parents were in health care. My ...
Challenges for Oncologists as They Reach Retirement Age
In 2014, The ASCO Post spoke with Mark J. Clemons, MB BS, BMedSci, MSc, MD, FRCP, FRCPC, of Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, about the retirement challenges faced by many oncologists. With market demand expected to exceed supply of oncologists soon, it is clear retirement is...
Assessing Value in Gastrointestinal Cancer Treatments
The era of precision oncology, in which molecular biomarkers are used to help guide drug delivery, has dovetailed with the emerging issues of value-based care and cost containment. To shed light on these issues and more, The ASCO Post spoke with Hanna K. Sanoff, MD, MPH, Clinical Medical Director...
Cancer Biologist Beatrice Mintz, PhD, FAACR, Dies at 100
The American Association for Cancer Research (AACR) issued the following statement regarding the passing of Beatrice Mintz, PhD, FAACR, a trailblazing pioneer in multiple fields of cancer biology, who died January 3, 2022, at the age of 100. Born on January 24, 1921, in New York, New York, Dr....
Cancer Has Made Me a Risk-Taker, and That’s Good
In 2017, I was caring for my brother, who was suffering from respiratory failure due to complications from cerebral palsy, and working full-time as a registered nurse. I was feeling overwhelmed and exhausted all the time. I was also losing weight at an alarming rate—more than 70 pounds in just a...
A Guide for Patients With Breast Cancer, Their Families, and Their Oncologists
Writing a comprehensive book about breast cancer that is also concise and highly readable is no easy task. However, the authors of The Breast Cancer Book: A Trusted Guide for You and Your Loved Ones have done that and more by deftly communicating science and medical content for the lay public....
An Adventurous Spirit Led to a Prominent Role in Radiation Oncology for Geraldine Jacobson, MD, MPH, MBA, FACR, FASTRO
Geraldine Jacobson, MD, MPH, MBA, FACR, FASTRO, founding Chair of the West Virginia University (WVU) Department of Radiation Oncology, was born in Fort Dix, New Jersey. Her father was a military officer, and his various duty posts offered an adventurous childhood for Dr. Jacobson. “One of my...
Project Catalyst: Educating Industry to Help Develop Successful Cancer Therapies
OCE Insights is written by members of the Oncology Center of Excellence (OCE) and the Office of Oncology Diseases (OOD) at the U.S. Food and Drug Administration. In this installment, Jeff Summers, MD, OOD Acting Associate Director for Translational Sciences, and Marc R. Theoret, MD, OCE Deputy...
Roswell Park Receives Nearly $1 Million to Address Race-Related Disparities in Prostate Cancer
African American men currently have the highest rates of prostate cancer in the United States and the poorest outcomes. New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and...
Adjuvant Atezolizumab in IMpower010: Moving the Needle in Early-Stage NSCLC
Adjuvant platinum-based chemotherapy for early-stage non–small cell lung cancer (NSCLC) is currently almost an afterthought and is taken for granted as a standard of care for patients with stage II to IIIA NSCLC after resection. The earliest meta-analysis, published in 1995,1 gave the first hint of ...
ASCO Statement on 50th Anniversary of Signing of National Cancer Act
“Fifty years ago, just a few days before the new year, former President Richard Nixon signed into law the National Cancer Act (NCA), setting a clear national priority to conquer cancer. “At the time the bill was signed into law, pioneers in our field had already made substantial discoveries, but we ...
Isatuximab-Containing Induction Therapy for Multiple Myeloma Increases Measurable Residual Disease Negativity
For the first-line treatment of newly diagnosed multiple myeloma, the percentage of patients achieving measurable residual disease (MRD, previously called minimal residual disease) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to a standard...
Expert Point of View: Laurie H. Sehn, MD, MPH
Press conference moderator, Laurie H. Sehn, MD, MPH, of the University of British Columbia, Vancouver, Canada, noted, that her center participated in the single-arm trial of mosunetuzumab. “We witnessed first-hand the tremendous capacity bispecific antibodies have to make a real difference in...
Better Federal Agency Coordination Is Needed to Accelerate Progress Against Cancer
President Richard M. Nixon signed the National Cancer Act into law on December 23, 1971. The unprecedented legislation granted sweeping authority to the Director of the National Cancer Institute (NCI) to develop a national cancer program that included the NCI, other research institutes, and federal ...
ZUMA-7: Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, examining second-line therapy for relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care. These findings were presented at the...
Expert Point of View: Steven J. Isakoff, MD, PhD
Steven J. Isakoff, MD, PhD, Director of Breast Cancer Clinical Research at Massachusetts General Hospital, Boston, found the TAMARISK study “interesting.” “Looking at genomic profiles of uterine cancer in both tamoxifen-associated uterine cancer, the researchers found a lower frequency of PIK3...
Durvalumab/Tremelimumab With or Without Radiotherapy in Resistant NSCLC
In a recent phase II clinical trial, the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab curtailed tumor growth in some patients with non–small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent. The addition of radiation therapy to the...
Developing a Comprehensive System for Personalized Survivorship-Centered Care Plans
By 2040, the number of cancer survivors in the United States is expected to climb from 17 million today to 26.1 million, with most living 5 years or more after their diagnosis. However, many of these survivors will need ongoing monitoring for treatment-related side effects and cancer recurrence...
Does Geography Play a Role in Early-Onset Colorectal Cancer in Young Black Men?
Although the incidence and mortality rates in colorectal cancer have dropped by 3.6% each year from 2007 to 2016 for people aged 55 and older—mainly because of increased colorectal cancer screening, advances in therapy, and reductions in smoking—these rates have increased by 2% each year during the ...
Imaging Biomarker May Help to Risk-Stratify Patients With Head and Neck Cancer
A team of scientists has used artificial intelligence (AI) to identify which patients with certain head and neck cancers may benefit from reducing the intensity of treatments such as radiation therapy and chemotherapy. Their findings were published by Corredor et al in the Journal of the National...
The Cancer Research Institute in Morocco: A Center of Excellence Illustrating Progress in Africa in the Age of Global Oncology
The enthusiasm behind the open access initiative sprang from the need for scientific research that is accessible to everyone worldwide. Open knowledge based on open access also aimed to increase good research practices such as reproducibility and transparency.1 This movement was launched by...
I Don’t Know Why I Got Young-Onset Colorectal Cancer
Throughout my adolescence and early adulthood, I had been plagued with digestive issues, including bouts of gastritis and constipation, which seemed normal for me and wasn’t too concerning. But by the time I turned 30, in 2015, the acid reflux I had been experiencing became so frequent and...
ASH Recognizes Choosing Wisely Champions at 63rd Annual Meeting
The American Society of Hematology (ASH) recognized three Choosing Wisely Champions—individuals working to tackle the overuse of hematology tests and treatments—at the 63rd ASH Annual Meeting & Exposition, held December 11–14 in Atlanta. Choosing Wisely is an initiative that seeks to advance a...
Diversity in Clinical Trials Career Development Program
The Bristol Myers Squibb Foundation, the National Medical Fellowships, and the American Association for Cancer Research (AACR) recently announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program. The 52 physicians selected by an independent...
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...
Study Examines Possible Clinical Trial Bias From Undisclosed Censoring
New research published by Wilson et al in JNCCN–Journal of the National Comprehensive Cancer Network found that only 59% of oncology clinical trials studied provided adequately defined rules for censoring. The researchers examined published randomized control trials supporting U.S. Food and Drug...
Isatuximab/RVd Meets Primary Endpoint of MRD Negativity for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
For the first-line treatment of newly diagnosed, transplant-eligible patients with multiple myeloma, the achievement of measurable residual disease (MRD) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to the standard three-drug induction regimen of...
I’m Living—and Thriving—With Stage IV Non–Small Cell Lung Cancer
A diagnosis, in 2020, of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) was found accidentally. I was 55 at the time and in the best physical shape of my life. I had spent the previous year and a half on a diet and exercise regimen that had rendered me 35 pounds lighter and feeling...
Update on the Role of Low-Dose Aspirin in Colorectal Cancer Prevention
Updating its 2016 recommendation on the use of aspirin to prevent cardiovascular disease and colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement. It noted the potential harms of daily aspirin, with the most serious being bleeding in the...
The High Price of Pain
According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2019, nearly 247,000 people died from overdoses involving prescription opioids in the United States. According to the CDC, the problem can be broken into three waves. The first began with an increase in prescribing...
The History of Medical Oncology in Europe, 1955–1985
In part 1 of this two-part review, we looked at early pioneers in the field of medical oncology in Europe, as well as the development of international cooperative trials and the formation of European oncology societies (see related articles below). In part 2, we explore how the field of medical...
The History of Medical Oncology in Europe, 1955–1985
Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...
Big Data and Vulnerable Populations: Addressing the Gap in Lung Cancer Screening
Recent advances in medical imaging have led to more accurate detection and management of early thoracic diseases such as lung cancer, chronic obstructive pulmonary disease (COPD), and cardiovascular disease—three of the top four leading causes of death in the United States. Unfortunately, if not...
Radiation Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma: Prospects and Controversies
In the treatment of patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma, neither cancer outcomes nor measurable quality of life have yet been shown to differ between surgery- and radiotherapy-based approaches, according to Sue S. Yom, MD, PhD, FASTRO, Professor of ...
Society for Integrative Oncology Focuses on the Science of Living Well With Cancer
Guest Editor’s Note: With the easing of some COVID-19 restrictions, the Society for Integrative Oncology (SIO) held its 2021 international conference in a hybrid format. It focused on the science of living well with cancer, challenges in designing integrative oncology research, and the role of...
How Medical Oncology Came to Be
For many, the way things are when you learn about them is assumed to be the way things have always been. For example, antibiotics are wonderful—but if you were practicing medicine when penicillin was discovered, it would have seemed like a miracle. For most of us, there have always been chemical...
Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care
Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...
Single-Cell Spatial Analysis May Help to Predict Response to Neoadjuvant Atezolizumab in Patients With Triple-Negative Breast Cancer
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab to chemotherapy as...
Sotigalimab Plus Nivolumab in Anti–PD-1/PD-L1–Refractory Melanoma
Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but a significant number of patients still fail to respond to anti–PD-1 therapy. The novel combination of sotigalimab, an anti-CD40 monoclonal antibody, and the PD-1 inhibitor nivolumab could help address this...
Effect of the COVID-19 Pandemic on Cancer Imaging
Significant decreases in computed tomography (CT) imaging for cancer persisted even after the peak of the COVID-19 pandemic in 2020—delaying diagnosis and treatment and raising the possibility of more advanced cancers and poorer outcomes for patients, according to a study presented at the...
